Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: An italian cohort study and overview of the literature

Marta Lionetti, Marzia Barbieri, Martina Manzoni, Sonia Fabris, Cecilia Bandini, Katia Todoerti, Filomena Nozza, Davide Rossi, Pellegrino Musto, Luca Baldini, Antonino Neri

Research output: Contribution to journalArticle

Abstract

The prevalence of TP53 mutations greatly varies between tumor types; in multiple myeloma (MM) they were rarely detected at presentation, while increased frequency was reported with disease progression. Using next-generation sequencing, we analyzed TP53 exons 4-9 in a large representative cohort comprising patients with MM at diagnosis and more aggressive forms of plasma cell (PC) dyscrasia, identifying mutations in 4/129 (3%) MM, 6/24 (25%) primary PC leukemia, and 2/10 (20%) secondary PC leukemia cases. A similar increase in prevalence associated with disease aggressiveness (5%, 29.2% and 44%, respectively) was observed for TP53 deletion. Interestingly, in five patients mutations were not concomitant with TP53 deletion. Furthermore, longitudinal analysis revealed the acquisition of TP53 mutations in three of nineteen cases analyzed at relapse. Identified variants were mostly missense mutations concentrated in the DNA binding domain, only partly reflecting the pattern globally observed in human cancers. Our data confirm that TP53 mutations are rare in MM at presentation and rather represent a marker of progression, similarly to del(17p); however, their occurrence even in absence of deletions supports the importance of their assessment in patients with PC dyscrasia, in terms of both risk stratification and therapeutic implications.

Original languageEnglish
Pages (from-to)21353-21361
Number of pages9
JournalOncotarget
Volume7
Issue number16
DOIs
Publication statusPublished - Apr 19 2016

    Fingerprint

Keywords

  • Multiple myeloma
  • Mutational analysis
  • Next-generation sequencing
  • Plasma cell leukemia
  • TP53

ASJC Scopus subject areas

  • Oncology

Cite this